5-benzyl-4-chloro-7H-pyrrolo[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 5-benzyl-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
• 化学式: C₁₃H₁₀ClN₃
• 分子量: 243.695
• InChiKey: YUCCNCNCIMMDBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-benzyl-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 、 螺[吲哚啉-3,4’-哌啶]-1’-羧酸苄酯 在 potassium dihydrogenphosphate 、 磷酸 作用下， 以 二甲基亚砜 为溶剂， 生成 benzyl 1-(5-benzyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Synthesis and structure based optimization of novel Akt inhibitors

  摘要：

  Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced potency. The syntheses of these series and their biological activities are described. Spiroindoline 13j is found to have an Akt1 kinase IC(50) of 2.4+/-0.6 nM, Akt cell potency of 50+/-19 nM, and provides 68% inhibition of tumor growth in a mouse xenograft model (50 mg/kg, qd, po).

  DOI：

  10.1016/j.bmcl.2008.04.034
• 作为产物：
  描述：

  (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(phenyl)methanol 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 5-benzyl-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  WO2006/90261

  摘要：

  公开号：

文献信息

• BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Morris Joel

  公开号：US20090111805A1

  公开（公告）日：2009-04-30

  The invention relates to compounds of the formula I: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, V, W, R 4 , R 5 , R 6 , R 7 , and ring B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I and to pharmaceutical compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of preparing the compounds of formula I.

  本发明涉及化合物I的公式，以及其药学上可接受的盐和溶剂化物，其中X、Z、V、W、R4、R5、R6、R7和环B的定义如本文所述。本发明还涉及通过给予公式I化合物治疗哺乳动物的异常细胞生长的方法，以及含有公式I化合物的用于治疗此类疾病的药物组合物。本发明还涉及制备公式I化合物的方法。
• [EN] BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES HETEROAROMATIQUES BICYCLIQUES UTILISES COMME AGENTS ANTICANCEREUX
  申请人：PFIZER PROD INC

  公开号：WO2006090261A1

  公开（公告）日：2006-08-31

  [EN] The invention relates to compounds of the formula I: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, V, W, R⁴, R⁵, R⁶, R⁷, and ring B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I and to pharmaceutical compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of preparing the compounds of formula I.
  [FR] La présente invention concerne des composés représentés par la formule (I) ainsi que des sels et solvates pharmaceutiquement acceptables de ceux-ci. Dans cette formule, X, Z, V, W, R⁴, R⁵, R⁶, R⁷ et le cycle B sont tels que définis dans la description. Cette invention porte également sur des méthodes de traitement d'une croissance cellulaire anormale chez des mammifères consistant à administrer les composés représentés par la formule (I), ainsi que sur des compositions pharmaceutiques servant au traitement de tels troubles et contenant les composés représentés par la formule (I). Cette invention concerne enfin des procédés de préparation des composés représentés par la formule (I).
• WO2006/90261
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis and structure based optimization of novel Akt inhibitors
  作者：Blaise Lippa、Gonghua Pan、Matthew Corbett、Chao Li、Goss S. Kauffman、Jayvardhan Pandit、Shaughnessy Robinson、Liuqing Wei、Ekaterina Kozina、Eric S. Marr、Gary Borzillo、Elisabeth Knauth、Elsa G. Barbacci-Tobin、Patrick Vincent、Merin Troutman、Deborah Baker、Francis Rajamohan、Shefali Kakar、Tracey Clark、Joel Morris

  DOI：10.1016/j.bmcl.2008.04.034

  日期：2008.6

  Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced potency. The syntheses of these series and their biological activities are described. Spiroindoline 13j is found to have an Akt1 kinase IC(50) of 2.4+/-0.6 nM, Akt cell potency of 50+/-19 nM, and provides 68% inhibition of tumor growth in a mouse xenograft model (50 mg/kg, qd, po).